[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377942-105":59,"doc-detail-377942-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immunotherapy-for-the-treatment-of-gastrointestinal-cancer","Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer","","Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, are a diverse set of malignancies with a major global burden. Immunotherapy has reshaped care, with immune checkpoint inhibitors (ICIs) producing durable responses and prolonged survival for selected patients in metastatic and resectable settings. SITC created an evidence- and consensus-based clinical practice guideline addressing biomarker testing, therapy selection, response monitoring, and patient education, while accounting for site-specific indications and ICI toxicity profiles versus standard systemic treatments.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immunotherapy-for-the-treatment-of-gastrointestinal-cancer/377942/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immunotherapy-for-the-treatment-of-gastrointestinal-cancer/377942.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which gastrointestinal (GI) cancer sites are covered in the guideline’s overview?","Question",{"text":113,"@type":114},"The document discusses GI cancers including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How have immune checkpoint inhibitors changed GI cancer treatment?",{"text":118,"@type":114},"ICIs targeting PD-1, alone or in combination regimens, have improved survival and provided durable responses for some patients in metastatic and resectable settings.",{"name":120,"@type":111,"acceptedAnswer":121},"Why do indications for ICIs in GI cancer differ across patients?",{"text":122,"@type":114},"ICI use requires careful consideration of biomarker positivity, histology, and the anatomic site of cancer origin, and ICIs also have toxicity profiles distinct from chemotherapy and other systemic treatments.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},377942,1790445845,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Open access Position article and guidelines  \nSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer  \nRonan J Kelly,1 Katherine Bever,2 Joseph Chao,3 Kristen K Ciombor,4 Cathy Eng,5  \nMarwan Fakih,6 Lipika Goyal,7 Joleen Hubbard,8 Renuka Iyer,9 Holly T Kemberling,10 Smitha Krishnamurthi,11 Geoffrey Ku  ,12 Mindy Mintz Mordecai,13 Van K Morris II,14 Andrew Scott Paulson,15 Valerie Peterson,16 Manish A Shah  ,17 Dung T Le2  \nTo cite: Kelly RJ, Bever K, Chao J, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. Journal for ImmunoTherapy of Cancer 2023;11:e006658 . doi:10 . 1136/ jitc-2022-006658  \nAccepted 09 April 2023  \n© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Ronan J Kelly;  \n[Ronan.Kelly@bswhealth.org](Ronan.Kelly@bswhealth.org)  \nABSTRACT  \nGastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and prolonged survival. Specifically, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1 (PD-1), either as monotherapies or in combination regimens, have gained tissue site-specific regulatory approvals for the treatment of metastatic disease and in the resectable setting. Indications for ICIs in GI cancer, however, have differing biomarker and histology requirements depending on the anatomic site of origin. Furthermore, ICIs are associated with unique toxicity profiles compared with other systemic treatments that have long been the mainstay for GI cancer, such as chemotherapy. With the goal of improving patient care by providing guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of GI cancer.  \nDrawing from published data and clinical experience, the expert panel developed evidence-and consensus-based recommendations for healthcare professionals using ICIsto treat GI cancers, with topics including biomarker testing, therapy selection, and patient education and quality of life considerations, among others.  \nINTRODUCTION  \nColorectal, liver, stomach, esophageal, and pancreas cancer account for more than onethird of cancer-related deaths worldwide. In the year 2022, there were an estimated 151,030 new cases of and 52,580 deaths due to colorectal cancer (CRC) in the US alone, making it the third most common cause of cancer-related death in this country.1 Stomach cancer led to an estimated 769,000  \ndeaths worldwide in 2020 and was the leading cause of cancer-related death in some Asian countries.2 While surgery, radiation, chemotherapy, liver-directed therapy, monoclonal antibodies, and targeted therapy offer some patients a meaningful response, many gastrointestinal (GI) tumors harbor mechanisms of resistance that will eventually overcome these conventional treatments and prevent patients from achieving long-term survival. In recent years, immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 (PD-1)/programmed death-ligand 1 (PDL1) axis as monotherapies or in combination with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) ICIs have been demonstrated to improve survival in biomarker selected GI tumors involving both the upper and lower tract3–5 and therefore, regimens including these agents have become standard of care (SOC) . However, not all patients benefit from ICIs, and their use","cbCaisZO3ugR3Bbl","https://ap.wps.com/l/cbCaisZO3ugR3Bbl","pdf",1570773,37,"English","# ABSTRACT\n# INTRODUCTION\n## Epidemiology and treatment challenges for GI cancers\n## Role of immune checkpoint inhibitors and biomarker requirements\n## Anatomic origin, biomarkers, and histology effects on response\n## Purpose and scope of the SITC clinical practice guideline","[{\"question\":\"Which gastrointestinal (GI) cancer sites are covered in the guideline’s overview?\",\"answer\":\"The document discusses GI cancers including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer.\"},{\"question\":\"How have immune checkpoint inhibitors changed GI cancer treatment?\",\"answer\":\"ICIs targeting PD-1, alone or in combination regimens, have improved survival and provided durable responses for some patients in metastatic and resectable settings.\"},{\"question\":\"Why do indications for ICIs in GI cancer differ across patients?\",\"answer\":\"ICI use requires careful consideration of biomarker positivity, histology, and the anatomic site of cancer origin, and ICIs also have toxicity profiles distinct from chemotherapy and other systemic treatments.\"}]","Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer | PDF",1790227752,93]